Healthcare Supply Chain Playbook »

Newly published by Healthcare Packaging, this 40-page playbook discusses how to create the right global shipping strategies, based on interviews with leading experts in the field. Download your copy today. Learn more »

 
Article tools:
|
Bookmark and Share

Cancer chemo patients improve quality of life; complex sugar drug DAVANAT proven in four FDA trials*

In four FDA trials, 97 cancer patients were dosed with a combination of chemotherapy and DAVANAT. During the trials, patients taking DAVANAT experienced significantly fewer serious side effects of chemotherapy including mucositis, gastrointestinal problems, loss of hair, nausea and vomiting according to Pro-Pharmaceuticals, Inc. DAVANAT targets the chemo into the tumors thereby protecting the healthy cells and reducing the chemo¹s side effects.

DAVANAT is a naturally occurring, complex sugar administered with chemotherapies and biologics to treat cancer. It is reported that $billions a year are spent on treating the side effects of chemotherapy. According to the National Cancer Institute, DAVANAT may be the next generation of cancer treatment that scientists have been struggling to find for the past four decades.

Pro-Pharmaceuticals, Inc., the exclusive developer of DAVANAT.

Liked this article? Start your subscription to Healthcare Packaging for FREE:

Sign up to receive the print magazine six times per year and the e-mail newsletter twice a month.

First Name:
Last Name:
 
Company:
Email Address:

 

* indicates a sponsored article that was submitted directly to this Web site by the supplier, and was not handled by the Healthcare Packaging editorial staff. Healthcare Packaging may share your contact information with our sponsors, as detailed in our Privacy Policy. Healthcare Packaging will not share your information with a sponsor whose content you have not reviewed.